Neoadjuvant PD-1 LAG-3 Antibody Melanoma Trial Results
Here’s a breakdown of teh key findings from the provided text regarding ctDNA (circulating tumor DNA) and its relationship to treatment response:
* High Detection Rate: ctDNA was detected in a very high percentage of patients (89.7%) even at early disease stages. This suggests ctDNA is a sensitive marker of disease presence.
* ctDNA Clearance & pathological Response: There’s a strong correlation between achieving a pathological response (meaning cancer cells are not found or considerably reduced after treatment) and clearing ctDNA.
* Good Response (pCR/npCR/pPR): 68% of patients with any degree of pathological response achieved ctDNA clearance by week 7 (before surgery).
* No Response (pNR): Only 25% of patients with no pathological response achieved ctDNA clearance.
* CPI Treatment & ctDNA Clearance: The use of CPI (likely checkpoint inhibitor) treatment led to increasing rates of ctDNA clearance:
* After 1 cycle: 50% of patients with pCR had ctDNA clearance.
* After 2 cycles: 77.3% of patients with pCR had ctDNA clearance.
* Figure 4: The figure illustrates the longitudinal changes in ctDNA levels over time, showing how ctDNA status changes with treatment and in relation to surgical intervention (TLND – Tumor Lymph Node Dissection). it visually demonstrates the correlation between treatment, ctDNA clearance, and pathological response.
In essence, the study suggests that ctDNA is a promising biomarker for monitoring treatment response.Clearance of ctDNA is associated with better pathological outcomes, and CPI treatment appears to drive ctDNA clearance in patients who respond well to therapy.